GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (OTCPK:ELTP) » Definitions » Price-to-Tangible-Book

Elite Pharmaceuticals (Elite Pharmaceuticals) Price-to-Tangible-Book : 3.40 (As of Apr. 26, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Elite Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-26), Elite Pharmaceuticals's share price is $0.1325. Elite Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.04. Hence, Elite Pharmaceuticals's Price to Tangible Book Ratio of today is 3.40.

The historical rank and industry rank for Elite Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

ELTP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.28   Med: 3.07   Max: 10
Current: 3.31

During the past 13 years, Elite Pharmaceuticals's highest Price to Tangible Book Ratio was 10.00. The lowest was 1.28. And the median was 3.07.

ELTP's Price-to-Tangible-Book is ranked worse than
64.49% of 873 companies
in the Drug Manufacturers industry
Industry Median: 2.36 vs ELTP: 3.31

A closely related ratio is called PB Ratio. As of today, Elite Pharmaceuticals's share price is $0.1325. Elite Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.05. Hence, Elite Pharmaceuticals's P/B Ratio of today is 2.88.


Elite Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Elite Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals Price-to-Tangible-Book Chart

Elite Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 6.78 1.94 1.32

Elite Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 1.32 1.67 2.47 3.59

Competitive Comparison of Elite Pharmaceuticals's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elite Pharmaceuticals's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Elite Pharmaceuticals's Price-to-Tangible-Book falls into.



Elite Pharmaceuticals Price-to-Tangible-Book Calculation

Elite Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=0.1325/0.039
=3.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Elite Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Elite Pharmaceuticals (Elite Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
Executives
Mark N Pellegrino officer: CFO, Secretary, Treasurer 165 LUDLOW AVE, NORTHVALE NJ 07647
Kirko Kirkov officer: Chief Commercial Officer 165 LUDLOW AVE, NORTHVALE NJ 07647
Chen Robert C J officer: CFO, Secretary, Treasurer 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Marc Bregman officer: CFO, Secretary, Treasurer C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Eugene M Pfeifer director C/O ELITE PHARMACEUTICALS, INC, 165, NORTHVALE NJ 07647
Davis S Caskey director C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVE, NORTHVALE NJ 07647
Jerry Treppel director 93 SETON HIGHLANDS, PLYMOUTH MA 02360
Mikah Pharma, Llc 10 percent owner 165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Plassche officer: Executive VP of Operations 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeenarine Narine director, 10 percent owner C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Ashok G Nigalaye director, 10 percent owner, officer: Chief Scientific Officer C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Epic Pharma Llc 10 percent owner 227-15 NORTH CONDUIT AVE, LAURELTON NY 11413-3134
Epic Investments, Llc 10 percent owner 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Nasrat A Hakim director, 10 percent owner, officer: President & CEO C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeffrey A Whitnell director C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVENUE, NORTHVALE NJ 07647

Elite Pharmaceuticals (Elite Pharmaceuticals) Headlines

From GuruFocus